サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1363983

呼吸器合胞体ウイルス診断の世界市場：2023-2030年

Global Respiratory Syncytial Virus Diagnostic Market 2023-2030
出版日: | 発行: Orion Market Research | ページ情報: 英文 120 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
呼吸器合胞体ウイルス診断の世界市場：2023-2030年
出版日: 2023年09月23日
発行: Orion Market Research
ページ情報: 英文 120 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の呼吸器合胞体ウイルス診断市場は、予測期間中（2023-2030年）にCAGR 6.5%の大幅な成長が見込まれています。呼吸器疾患の罹患率の上昇、新生児人口の増加、体外診断のニーズの拡大、ポイントオブケア施設に対する需要の高まりは、市場拡大を後押しする主な理由のいくつかです。2022年11月に発表された米国立衛生研究所（NIH）の報告書によると、小児の90.0％が生後2年以内にRSVに罹患し、成人や年長児も頻繁に再罹患します。RSV患者の大部分は上気道炎を経験しますが、かなりの割合で下気道炎（主に細気管支炎）も経験します。例えば、米国では2023年7月、アストラゼネカとサノフィが製造するベイフォルタス（ニルセビマブ）が、新生児、乳児、および最初のRSVシーズンに生まれたか始まったばかりの生後24ヵ月までの小児における呼吸器合胞体ウイルス（RSV）下気道疾患（LRTD）の治療薬として承認されました。

セグメント別の見通し

分子診断サブセグメントが世界の呼吸器合胞体ウイルス診断市場で大きなシェアを占めると予想される

呼吸器合胞体ウイルス診断の世界市場では、診断法の中でも分子診断サブセグメントが大きなシェアを占めると予想されています。同分野の成長は、世界人口における慢性疾患の影響の増加によるもので、呼吸器疾患は頻繁に増加すると予測されています。このため、RSVのような感染症を検査するための分子診断市場への需要も増加すると予測されています。例えば、2021年3月、GENETWORx Labsは、インフルエンザA-B、COVID-19、RSVの3つの異なる呼吸器ウイルスを1つの検査サンプルで早期に同定できる診断検査を発表しました。TCA/GENETWORx Flu A-B/COVID Combo Testは、インフルエンザAおよびBウイルスを同定し、RSVおよびCOVID-19の原因ウイルスであるSARS-CoV-2と区別する分子診断PCR検査です。また、A型とB型の2種類のインフルエンザウイルスを検出します。

地域別展望

世界の呼吸器合胞体ウイルス診断市場は、北米（米国とカナダ）、欧州（英国、イタリア、スペイン、ドイツ、フランス、その他欧州地域）、アジア太平洋地域（インド、中国、日本、韓国、その他アジア地域）、世界のその他の地域（中東とアフリカ、中南米）を含む地域別にさらに細分化されています。なかでもアジア太平洋地域は、呼吸器合胞体ウイルス感染症の負担が増加していることから、世界全体で大きなシェアを占めると予想されています。投資の増加、技術開発、製品の承認と新興国市場の発展、政府の取り組み、その他市場参入企業による主な戦略。主な参入企業には、Jacobson Pharma、Ascletis Pharma Inc.、Nuance Pharma、Sino BioogicalInc.、VedaLabなどがあります。

呼吸器合胞体ウイルス診断の世界市場では北米がCAGRで大きく成長する見込み

すべての地域の中で、北米地域は予測期間中にかなりのCAGRで成長すると予測されています。この地域の成長は、バイオテクノロジーやナノテクノロジー（PCR）のような近代的手法の開発が、ウェスタンブロット、酵素結合免疫吸着試験（ELISA）、直接免疫蛍光、リアルタイムポリメラーゼ連鎖反応を含むRSV検出技術の開発に役立っていることに起因しています。さらに、多くの国の政府機関が、新しい治療法を生み出すための研究開発イニシアチブに資金を提供しています。臨床ワクチン研究の増加、体外診断の必要性の増加、小児肺炎の有病率の増加、分子診断の使用の増加は、市場を推進すると予想される追加要因です。これらは、この地域における市場拡大の具体的な要因です。

他の検査法に比べて迅速抗原検査が有効であること、製品導入が増加していること、政府や市場参入企業の活動が活発であることなどが、この地域の成長を促進すると予想されます。乳幼児におけるRSV感染の増加米国アレルギー感染症研究所（NIAID）が2022年7月に発表した報告書によると、RSV感染により米国では65歳以上の成人が毎年14,000人死亡しています。RSVは全世界で毎年6,400万人が感染し、16万人が死亡すると考えられています。特異性が高く、内部チェックが可能で、迅速な結果が得られることから、分子的アプローチは有望です。患者群における免疫測定法と比較して、分子診断法はこの地域でより広く使用されるようになってきています。

目次

第1章 レポート概要

  • 業界の現状分析と成長可能性の展望
  • 調査方法とツール
  • 市場内訳
    • セグメント別
    • 地域別

第2章 市場概要と洞察

  • 調査範囲
  • アナリストの洞察と現在の市場動向
    • 主な調査結果
    • 推奨事項
    • 結論

第3章 競合情勢

  • 主要企業分析
  • Becton, Dickinson and Company
    • 概要
    • 財務分析
    • SWOT分析
    • 最近の動向
  • BioMerieux SA
    • 概要
    • 財務分析
    • SWOT分析
    • 最近の動向
  • F. Hoffmann-La Roche Ltd.
    • 概要
    • 財務分析
    • SWOT分析
    • 最近の動向
  • 主要戦略分析

第4章 市場セグメンテーション

  • 世界の呼吸器合胞体ウイルス診断市場：製品別
    • キット・アッセイ
    • 装置
  • 世界の呼吸器合胞体ウイルス診断市場：検査法別
    • 迅速抗原検出検査
    • 分子診断法
    • 直接蛍光抗体法
    • 免疫測定法
    • その他（フローサイトメトリー）
  • 世界の呼吸器合胞体ウイルス診断市場：エンドユーザー別
    • 病院
    • 診療所
    • 研究所

第5章 地域別分析

  • 北米
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • イタリア
    • スペイン
    • フランス
    • その他欧州
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • 韓国
    • その他アジア太平洋
  • 世界のその他の地域

第6章 企業プロファイル

  • Abbott Laboratories
  • Beckman Coulter Inc.
  • BioCartis, Hologic, Inc
  • Bio-Rad Laboratories, Inc.
  • CorisBioConcept
  • Danaher
  • DiaSorin Molecular LLC.
  • Fast Track Diagnostics Luxembourg S.a R.L.
  • Luminex Corp.
  • Merck KGaA
  • NorgenBiotek Corp.
  • Ortho Clinical Diagnostics
  • Quest Diagnostics
  • QuidelOrtho Corporation
  • Siemens Healthcare Diagnostics Inc.
  • Virax Biolabs
図表

LIST OF TABLES

  • 1. GLOBAL RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET RESEARCH AND ANALYSIS BY PRODUCT, 2022-2030 ($ MILLION)
  • 2. GLOBAL RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC KITS AND ASSAYS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 3. GLOBAL RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC INSTRUMRNT MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 4. GLOBAL RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET RESEARCH AND ANALYSIS BY METHOD, 2022-2030 ($ MILLION)
  • 5. GLOBAL RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC VIA RAPID ANTIGEN DETECTION TESTS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 6. GLOBAL RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC VIA MOLECULAR DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 7. GLOBAL RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC VIA DIRECT FLUORESCENT ANTIBODY METHOD MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 8. GLOBAL RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC VIA IMMUNOASSAYS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 9. GLOBAL OTHERS RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 10. GLOBAL RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET RESEARCH AND ANALYSIS BY END-USERS, 2022-2030 ($ MILLION)
  • 11. GLOBAL RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC IN HOSPITALS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 12. GLOBAL RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC IN CLINICS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 13. GLOBAL RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC IN LABORATORIES MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 14. GLOBAL RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 15. NORTH AMERICAN RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 16. NORTH AMERICAN RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET RESEARCH AND ANALYSIS BY PRODUCT, 2022-2030 ($ MILLION)
  • 17. NORTH AMERICAN RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET RESEARCH AND ANALYSIS BY METHOD, 2022-2030 ($ MILLION)
  • 18. NORTH AMERICAN RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET RESEARCH AND ANALYSIS BY END-USERS, 2022-2030 ($ MILLION)
  • 19. EUROPEAN RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 20. EUROPEAN RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET RESEARCH AND ANALYSIS BY PRODUCT, 2022-2030 ($ MILLION)
  • 21. EUROPEAN RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET RESEARCH AND ANALYSIS BY METHOD, 2022-2030 ($ MILLION)
  • 22. EUROPEAN RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET RESEARCH AND ANALYSIS BY END-USERS, 2022-2030 ($ MILLION)
  • 23. ASIA- PACIFIC RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 24. ASIA- PACIFIC RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET RESEARCH AND ANALYSIS BY PRODUCT, 2022-2030 ($ MILLION)
  • 25. ASIA- PACIFIC RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET RESEARCH AND ANALYSIS BY METHOD, 2022-2030 ($ MILLION)
  • 26. ASIA- PACIFIC RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET RESEARCH AND ANALYSIS BY END-USERS, 2022-2030 ($ MILLION)
  • 27. REST OF THE WORLD RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 28. REST OF THE WORLD RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET RESEARCH AND ANALYSIS BY PROUCT, 2022-2030 ($ MILLION)
  • 29. REST OF THE WORLD RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET RESEARCH AND ANALYSIS BY METHOD, 2022-2030 ($ MILLION)
  • 30. REST OF THE WORLD RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET RESEARCH AND ANALYSIS BY END-USERS, 2022-2030 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET RESEARCH AND ANALYSIS BY PRODUCT, 2022 VS 2030 (%)
  • 2. GLOBAL RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC KITS AND ASSAYS MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 3. GLOBAL RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC INSTRUMRNT MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 4. GLOBAL RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET RESEARCH AND ANALYSIS BY METHOD, 2022 VS 2030 (%)
  • 5. GLOBAL RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC VIA RAPID ANTIGEN DETECTION TESTS MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 6. GLOBAL RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC VIA MOLECULAR DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 7. GLOBAL RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC VIA DIRECT FLUORESCENT ANTIBODY METHOD MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 8. GLOBAL RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC VIA IMMUNOASSAYS MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 9. GLOBAL OTHERS RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 10. GLOBAL RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET RESEARCH AND ANALYSIS BY END-USERS, 2022 VS 2030 (%)
  • 11. GLOBAL RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC IN HOSPITALS MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 12. GLOBAL RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC IN CLINICS MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 13. GLOBAL RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC IN LABORATORIES MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 14. GLOBAL RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 15. GLOBAL RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 16. US RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET SIZE, 2022-2030 ($ MILLION)
  • 17. CANADA RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET SIZE, 2022-2030 ($ MILLION)
  • 18. UK RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET SIZE, 2022-2030 ($ MILLION)
  • 19. FRANCE RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET SIZE, 2022-2030 ($ MILLION)
  • 20. GERMANY RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET SIZE, 2022-2030 ($ MILLION)
  • 21. ITALY RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET SIZE, 2022-2030 ($ MILLION)
  • 22. SPAIN RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET SIZE, 2022-2030 ($ MILLION)
  • 23. REST OF EUROPE RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET SIZE, 2022-2030 ($ MILLION)
  • 24. INDIA RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET SIZE, 2022-2030 ($ MILLION)
  • 25. CHINA RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET SIZE, 2022-2030 ($ MILLION)
  • 26. JAPAN RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET SIZE, 2022-2030 ($ MILLION)
  • 27. SOUTH KOREA RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET SIZE, 2022-2030 ($ MILLION)
  • 28. REST OF ASIA-PACIFIC RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET SIZE, 2022-2030 ($ MILLION)
  • 29. REST OF THE WORLD RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET SIZE, 2022-2030 ($ MILLION)
目次
Product Code: OMR2027690

Title: Global Respiratory Syncytial Virus Diagnostic Market Size, Share & Trends Analysis Report by Product (Kits and Assays, Instruments), by Method (Rapid Antigen Detection Tests, Molecular Diagnostics, Direct Fluorescent Antibody Method, Immunoassays and Others), and by End-Users (Hospitals, Clinics, and Laboratories),Forecast Period (2023-2030).

The global respiratory syncytial virus diagnostic market is anticipated to grow at a significant CAGR of 6.5% during the forecast period (2023-2030). Rising incidence rates of respiratory illnesses, increasing newborn populations, an expanding need for in-vitro diagnostics, and rising demand for point-of-care facilities are a few of the main reasons propelling market expansion. According to a National Institute of Health (NIH) report published in November 2022, 90.0% of children get RSV within the first two years of life, and adults and older children frequently get it again. The majority of RSV patients will experience upper respiratory sickness, but a sizeable proportion will also experience lower respiratory illness, primarily bronchiolitis. For instance, in July 2023, US approved Beyfortus (nirsevimab), Manufactured by AstraZeneca and Sanofi, for the treatment of respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) in newborns, infants, and children up to 24 months old who were born during or just beginning their first RSV season.

Segmental Outlook

The global respiratory syncytial virus diagnostic market is segmented on the product, method, and end-users. Based on the product, the market is sub-segmented into kits and assays, and instruments. Based on the method, the market is sub-segmented into rapid antigen detection tests, molecular diagnostics, direct fluorescent antibody methods, immunoassays, and others. Further, on the basis of end-users, the market is sub-segmented into hospitals, clinics, and laboratories. Among the products, the kits and assay sub-segment is anticipated to hold a considerable share of the market owing to the increase in the development of a fluorescent focus-based, high-throughput microneutralization test for the respiratory syncytial virus.

The Molecular Diagnostics Sub-Segment is Anticipated to Hold a Considerable Share of the Global Respiratory Syncytial Virus Diagnostic Market

Among the methods, the molecular diagnostics sub-segment is expected to hold a considerable share of the global respiratory syncytical virus diagnosis market. The segmental growth is attributed to the increasing impact of chronic diseases on the global population; respiratory illnesses are projected to grow frequently. This is also anticipated to increase demand for molecular diagnostics in the market for testing infectious diseases like RSV. For instance, in March 2021, GENETWORx Labs announced a diagnostic test that combines the early identification of all three distinct respiratory viruses-Flu A-B, COVID-19, and RSV-in a single test sample for patients. The TCA/GENETWORx Flu A-B/COVID Combo Test is a molecular diagnostic PCR test that identifies influenza A and B viruses and distinguishes them from RSV and SARS-CoV-2, the virus that causes COVID-19. It also detects two types of influenza viruses, influenza A and B.

Regional Outlook

The global respiratory syncytial virus diagnostic market is further segmented based on geography, including North America (the US and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia), and the Rest of the World (the Middle East & Africa, and Latin America). Among these, Asia-Pacific is anticipated to hold a prominent share of the market across the globe, owing to the increased burden of respiratory syncytial virus infections in the region. Rise in investments, technical development, product approvals and launches, government efforts, and other major strategies taken by the key market participants. The key players include Jacobson Pharma, Ascletis Pharma Inc., Nuance Pharma, Sino BioogicalInc.,VedaLab and others.

The North America is Anticipated to Grow at a Significant CAGR in the Global Respiratory Syncytial Virus Diagnostic Market

Among all regions, the North America regions is anticipated to grow at a considerable CAGR over the forecast period. Regional growth is attributed to development of modern methods like bio- and nanotechnology (PCR) are helping to develop RSV detection technologies including the western blot, enzyme-linked immunosorbent test (ELISA), direct immunofluorescence, and real-time polymerase chain reaction. In addition, government organizations from many nations provide funding for R&D initiatives to create new treatments. A rise in the number of clinical vaccine studies, an increase in the need for in-vitro diagnostics, an increase in the prevalence of pediatric pneumonia, and a rise in the use of molecular diagnostics are additional factors anticipated to propel the market. These are the specific factors driving market expansion in the region.

Rapid antigen test effectiveness compared to other procedures, increasing product introductions, and significant government and market participant activities are all anticipated to enhance regional growth. Owing to the higher occurrence of RSV infections in babies and young children. According to National Institute of Allergy and Infectious Disease (NIAID), report published in July 2022, According to estimates, RSV infection cause 14,000 death in US adults over 65 each year. RSV is thought to affect 64 million people globally each year, and cause death of 160,000 people globally. With their great specificity, internal checks, and rapid turnaround times, molecular approaches hold promise. Compared to immunoassays in the patient group, molecular diagnostics are becoming more widely used in the region.

Market Players Outlook

The major companies serving the respiratory syncytial virus includes diagnostic market Abbott Laboratories, Bio-Rad Laboratories, Inc., DiaSorin Molecular LLC., NorgenBiotek Corp., Siemens Healthcare Diagnostics Inc. and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in February 2021, BARDA and Luminex Corp. collaborate on a single, rapid diagnostic test to distinguish coronavirus from influenza and RSV infections. With the help of this grant from BARDA, Luminex Corporation will be able to complete the development work necessary to submit an application to the FDA for Emergency Use Authorization (EUA) of the ARIES Flu A/B & RSV+SARS-CoV-2 Assay and to get 510(k) clearance for this combo test.

The Report Covers:

  • Market value data analysis of 2022 and forecast to 2030.
  • Annualized market revenues ($ million) for each market segment.
  • Country-wise analysis of major geographical regions.
  • Key companies operating in the global respiratory syncytial virus diagnostic market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
  • Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
  • Analysis of market-entry and market expansion strategies.
  • Competitive strategies by identifying 'who-stands-where' in the market.

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Region

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Key Company Analysis
  • 3.2. Becton, Dickinson and Company
    • 3.2.1. Overview
    • 3.2.2. Financial Analysis
    • 3.2.3. SWOT Analysis
    • 3.2.4. Recent Developments
  • 3.3. BioMerieux SA
    • 3.3.1. Overview
    • 3.3.2. Financial Analysis
    • 3.3.3. SWOT Analysis
    • 3.3.4. Recent Developments
  • 3.4. F. Hoffmann-La Roche Ltd.
    • 3.4.1. Overview
    • 3.4.2. Financial Analysis
    • 3.4.3. SWOT Analysis
    • 3.4.4. Recent Developments
  • 3.5. Key Strategy Analysis

4. Market Segmentation

  • 4.1. Global Respiratory Syncytial Virus Diagnostic Market by Product
    • 4.1.1. Kits and Assays
    • 4.1.2. Instruments
  • 4.2. Global Respiratory Syncytial Virus Diagnostic Market by Method
    • 4.2.1. Rapid Antigen Detection Tests
    • 4.2.2. Molecular Diagnostics
    • 4.2.3. Direct Fluorescent Antibody Method
    • 4.2.4. Immunoassays
    • 4.2.5. Others (Flow Cytometry)
  • 4.3. Global Respiratory Syncytial Virus Diagnostic Market by End-Users
    • 4.3.1. Hospitals
    • 4.3.2. Clinics
    • 4.3.3. Laboratories

5. Regional Analysis

  • 5.1. North America
    • 5.1.1. United States
    • 5.1.2. Canada
  • 5.2. Europe
    • 5.2.1. UK
    • 5.2.2. Germany
    • 5.2.3. Italy
    • 5.2.4. Spain
    • 5.2.5. France
    • 5.2.6. Rest of Europe
  • 5.3. Asia-Pacific
    • 5.3.1. China
    • 5.3.2. India
    • 5.3.3. Japan
    • 5.3.4. South Korea
    • 5.3.5. Rest of Asia-Pacific
  • 5.4. Rest of the World

6. Company Profiles

  • 6.1. Abbott Laboratories
  • 6.2. Beckman Coulter Inc.
  • 6.3. BioCartis, Hologic, Inc
  • 6.4. Bio-Rad Laboratories, Inc.
  • 6.5. CorisBioConcept
  • 6.6. Danaher
  • 6.7. DiaSorin Molecular LLC.
  • 6.8. Fast Track Diagnostics Luxembourg S.a R.L.
  • 6.9. Luminex Corp.
  • 6.10. Merck KGaA
  • 6.11. NorgenBiotek Corp.
  • 6.12. Ortho Clinical Diagnostics
  • 6.13. Quest Diagnostics
  • 6.14. QuidelOrtho Corporation
  • 6.15. Siemens Healthcare Diagnostics Inc.
  • 6.16. Virax Biolabs